Thor Medical (TRMED) R&D Day 2021 summary

Strategic vision

• Strategy focused on building value from Betalutin beyond the pivotal Phase 2b PARADIGME trial and developing broader CD37-targeted opportunities in blood cancers and immune diseases.

• CD37 was presented as a validated target, with Betalutin positioned for potential use across NHL indications where its profile could address unmet needs.

Betalutin development

• Planned clinical expansion includes earlier-line follicular lymphoma (FL) and other NHL subtypes, including diffuse large B-cell lymphoma (DLBCL); prior study insights are expected to inform development.

• Presentations were set to cover CMC preparation for a Betalutin BLA and launch-readiness work, contingent on successful clinical and regulatory processes.

CD37 pipeline

• Pipeline opportunities include Humalutin, a lutetium-177 radioimmunotherapy candidate for NHL, and Alpha37, a lead-212 alpha-emitting candidate being explored with Oranomed for relapsed/refractory CLL.

• Other opportunities include a fully humanized anti-CD37 antibody for blood cancers and autoimmune diseases, and a CD37 DOTA CAR-T cell program in collaboration with the University of Pennsylvania.